impact of a best practices program in patients with relapsed/refractory mm receiving selinexor
Published 6 months ago • 196 plays • Length 47:16Download video MP4
Download video MP3
Similar videos
-
37:23
predictors of unsustained measurable residual disease negativity in patients with multiple myeloma
-
4:59
selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leuk...
-
1:01:58
novel agents in myeloma: different targets and mechanisms of action
-
9:21
positive results of selinexor in relapsed and refractory myeloma patients presented at ash 2019
-
52:12
the 1st online master class in transplantation and hematology (math) - session 1
-
1:16:50
the 1st online master class in transplantation and hematology (math) - session 4
-
38:34
selinexor, bortezomib, and dexamethasone versus bortezomib & dexamethasone in previously treated mm
-
54:11
nursing care and frailty in myeloma
-
![[webinar] ich e9(r1) addendum on estimands and sensitivity analysis](https://i.ytimg.com/vi/CdT_EbwPNFA/mqdefault.jpg)
40:18
[webinar] ich e9(r1) addendum on estimands and sensitivity analysis
-
7:28
new excel textsplit function to separate words with ease (includes cool tips)
-
9:04
potential benefits of selinexor for car-t therapies
-
43:46
the simplified comorbidity index: a new tool for prediction of nonrelapse mortality in allo-hct
-
57:12
hsct mobilization strategies in multiple myeloma
-
1:03:03
the 1st online master class in transplantation and hematology (math) - session 2
-
1:02:23
selinexor, carfilzomib, and dexamethasone in treating patients with relapsed or refractory myeloma
-
5:54
rrmm: incorporation of selinexor into clinical practice
-
38:38
the 1st online master class in transplantation and hematology (math) - session 3
-
1:57
dr. chari on using selinexor in multiple myeloma treatment
-
6:10
impact of prior therapies on selinexor, bortezomib and dex in r/r mm
-
1:41
dr. martin on selinexor in penta-refractory patients with myeloma
-
3:50
selinexor: a clear role in heavily pre-treated multiple myeloma
-
38:16
management of patients receiving anticd38 (supporting tools on how to manage them, aes)